Raymond James Financial Inc. Purchases Shares of 84,091 Roivant Sciences Ltd. (NASDAQ:ROIV)

Raymond James Financial Inc. purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 84,091 shares of the company's stock, valued at approximately $995,000.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. Quarry LP increased its position in Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company's stock worth $87,000 after buying an additional 2,500 shares during the period. Blue Trust Inc. lifted its stake in Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after buying an additional 6,667 shares during the last quarter. Raab & Moskowitz Asset Management LLC acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $127,000. Finally, FSA Advisors Inc. purchased a new position in shares of Roivant Sciences during the fourth quarter worth approximately $130,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on ROIV shares. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Remove Ads

Roivant Sciences Stock Down 1.9 %

Shares of NASDAQ ROIV traded down $0.18 during mid-day trading on Tuesday, hitting $9.08. 7,152,378 shares of the company were exchanged, compared to its average volume of 5,363,568. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of -60.53 and a beta of 1.25. The stock has a 50 day simple moving average of $10.50 and a 200-day simple moving average of $11.27. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the transaction, the chief operating officer now directly owns 732,294 shares of the company's stock, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm's stock in a transaction on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 1,395,541 shares of company stock worth $15,028,538. Corporate insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.